AU6648898A - Treatment of autoimmune disease using tolerization in combination with methotrexate - Google Patents
Treatment of autoimmune disease using tolerization in combination with methotrexateInfo
- Publication number
- AU6648898A AU6648898A AU66488/98A AU6648898A AU6648898A AU 6648898 A AU6648898 A AU 6648898A AU 66488/98 A AU66488/98 A AU 66488/98A AU 6648898 A AU6648898 A AU 6648898A AU 6648898 A AU6648898 A AU 6648898A
- Authority
- AU
- Australia
- Prior art keywords
- methotrexate
- disease
- autoimmune
- antigen
- bystander
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B41—PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
- B41J—TYPEWRITERS; SELECTIVE PRINTING MECHANISMS, i.e. MECHANISMS PRINTING OTHERWISE THAN FROM A FORME; CORRECTION OF TYPOGRAPHICAL ERRORS
- B41J2/00—Typewriters or selective printing mechanisms characterised by the printing or marking process for which they are designed
- B41J2/005—Typewriters or selective printing mechanisms characterised by the printing or marking process for which they are designed characterised by bringing liquid or particles selectively into contact with a printing material
- B41J2/01—Ink jet
- B41J2/21—Ink jet for multi-colour printing
- B41J2/2107—Ink jet for multi-colour printing characterised by the ink properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06K—GRAPHICAL DATA READING; PRESENTATION OF DATA; RECORD CARRIERS; HANDLING RECORD CARRIERS
- G06K2215/00—Arrangements for producing a permanent visual presentation of the output data
- G06K2215/0082—Architecture adapted for a particular function
- G06K2215/0094—Colour printing
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06K—GRAPHICAL DATA READING; PRESENTATION OF DATA; RECORD CARRIERS; HANDLING RECORD CARRIERS
- G06K2215/00—Arrangements for producing a permanent visual presentation of the output data
- G06K2215/0082—Architecture adapted for a particular function
- G06K2215/0097—Printing on special media, e.g. labels, envelopes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3672297P | 1997-01-24 | 1997-01-24 | |
US60036722 | 1997-01-24 | ||
PCT/US1998/001648 WO1998032451A1 (en) | 1997-01-24 | 1998-01-26 | Treatment of autoimmune disease using tolerization in combination with methotrexate |
Publications (1)
Publication Number | Publication Date |
---|---|
AU6648898A true AU6648898A (en) | 1998-08-18 |
Family
ID=21890248
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU66488/98A Abandoned AU6648898A (en) | 1997-01-24 | 1998-01-26 | Treatment of autoimmune disease using tolerization in combination with methotrexate |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP0994717A4 (ja) |
JP (1) | JP2001511134A (ja) |
KR (1) | KR20000070460A (ja) |
AU (1) | AU6648898A (ja) |
BR (1) | BR9807112A (ja) |
CA (1) | CA2278152A1 (ja) |
HU (1) | HUP0001960A2 (ja) |
IL (1) | IL131025A0 (ja) |
NO (1) | NO993600L (ja) |
WO (1) | WO1998032451A1 (ja) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE409057T1 (de) | 2002-02-11 | 2008-10-15 | Antares Pharma Inc | Intradermales injektionsgerät |
WO2006079064A1 (en) | 2005-01-24 | 2006-07-27 | Antares Pharma, Inc. | Prefilled needle assisted jet injector |
GB0523576D0 (en) * | 2005-11-18 | 2005-12-28 | Theradeas Ltd | Drug composition and its use in therapy |
US8251947B2 (en) | 2006-05-03 | 2012-08-28 | Antares Pharma, Inc. | Two-stage reconstituting injector |
US9144648B2 (en) | 2006-05-03 | 2015-09-29 | Antares Pharma, Inc. | Injector with adjustable dosing |
WO2009114542A1 (en) | 2008-03-10 | 2009-09-17 | Antares Pharma, Inc. | Injector safety device |
ES2738539T3 (es) | 2008-08-05 | 2020-01-23 | Antares Pharma Inc | Inyector de dosis múltiples |
CA2755779C (en) | 2009-03-20 | 2015-11-10 | Antares Pharma, Inc. | Hazardous agent injection system |
EP2799071B1 (en) | 2010-06-16 | 2018-10-17 | Inflammatory Response Research, Inc. | Levocetirizine and montelukast for the treatment of influenza and common cold |
US8496619B2 (en) | 2011-07-15 | 2013-07-30 | Antares Pharma, Inc. | Injection device with cammed ram assembly |
US9220660B2 (en) | 2011-07-15 | 2015-12-29 | Antares Pharma, Inc. | Liquid-transfer adapter beveled spike |
FI2822618T3 (fi) | 2012-03-06 | 2024-03-21 | Antares Pharma Inc | Esitäytetty injektioruisku laukeamisvoimaominaisuuden kera |
KR20150011346A (ko) | 2012-04-06 | 2015-01-30 | 안타레스 팔마, 인코퍼레이티드 | 테스토스테론 조성물의 바늘-보조식 젯 주입 투여 장치 및 방법 |
WO2013169800A1 (en) | 2012-05-07 | 2013-11-14 | Antares Pharma, Inc. | Injection device with cammed ram assembly |
FI3659647T3 (fi) | 2013-02-11 | 2024-03-28 | Antares Pharma Inc | Neula-avusteinen suihkuinjektiolaite, jolla on pienennetty liipaisinvoima |
WO2014164786A1 (en) | 2013-03-11 | 2014-10-09 | Madsen Patrick | Dosage injector with pinion system |
WO2014165136A1 (en) | 2013-03-12 | 2014-10-09 | Antares Pharma, Inc. | Constant volume prefilled syringes and kits thereof |
JP2016512262A (ja) | 2013-03-13 | 2016-04-25 | インフラマトリー・レスポンス・リサーチ・インコーポレイテッド | 血管炎の処置におけるレボセチリジン及びモンテルカストの使用 |
ES2660494T3 (es) | 2013-03-13 | 2018-03-22 | 14779507 | Uso de levocetirizina y montelukast en el tratamiento de una lesión traumática |
EP3300734B1 (en) | 2013-03-13 | 2019-08-14 | Inflammatory Response Research, Inc. | Use of levocetirizine and montelukast in the treatment of autoimmune disorders |
JP2017526728A (ja) | 2014-09-15 | 2017-09-14 | インフラマトリー・レスポンス・リサーチ・インコーポレイテッド | 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5571499A (en) * | 1987-06-24 | 1996-11-05 | Autoimmune, Inc. | Treatment of autoimmune diseases by aerosol administration of autoantigens |
ATE130762T1 (de) * | 1987-06-24 | 1995-12-15 | Autoimmune Inc | Behandlung von autoimmun-erkrankungen durch orale verabreichung von autoantigenen. |
US5571500A (en) * | 1987-06-24 | 1996-11-05 | Autoimmune, Inc. | Treatment of autoimmune diseases through administration by inhalation of autoantigens |
JPH05507501A (ja) * | 1990-09-06 | 1993-10-28 | リックスウーニーベルシテイト・テ・ウットレヒト | リンパ球応答と免疫関連疾患との阻害剤 |
CA2117492C (en) * | 1992-02-28 | 2009-04-07 | Howard L. Weiner | Bystander suppression of autoimmune diseases |
AU5960096A (en) * | 1995-06-07 | 1996-12-30 | Nexstar Pharmaceuticals, Inc. | Method to use superantigens to target subpopulations of t ce lls |
DE69627855T2 (de) * | 1995-06-13 | 2004-03-11 | Nippon Meat Packers, Inc. | Orales mittel gegen rheumatische arthritis und funktionelles nahrungsmittel |
-
1998
- 1998-01-26 KR KR1019997006698A patent/KR20000070460A/ko not_active Application Discontinuation
- 1998-01-26 IL IL13102598A patent/IL131025A0/xx unknown
- 1998-01-26 BR BR9807112-2A patent/BR9807112A/pt not_active Application Discontinuation
- 1998-01-26 AU AU66488/98A patent/AU6648898A/en not_active Abandoned
- 1998-01-26 HU HU0001960A patent/HUP0001960A2/hu unknown
- 1998-01-26 EP EP98908452A patent/EP0994717A4/en not_active Withdrawn
- 1998-01-26 WO PCT/US1998/001648 patent/WO1998032451A1/en not_active Application Discontinuation
- 1998-01-26 CA CA002278152A patent/CA2278152A1/en not_active Abandoned
- 1998-01-26 JP JP53225298A patent/JP2001511134A/ja active Pending
-
1999
- 1999-07-23 NO NO993600A patent/NO993600L/no unknown
Also Published As
Publication number | Publication date |
---|---|
CA2278152A1 (en) | 1998-07-30 |
IL131025A0 (en) | 2001-01-28 |
JP2001511134A (ja) | 2001-08-07 |
HUP0001960A2 (hu) | 2000-10-28 |
NO993600L (no) | 1999-09-23 |
KR20000070460A (ko) | 2000-11-25 |
BR9807112A (pt) | 2001-09-18 |
NO993600D0 (no) | 1999-07-23 |
WO1998032451A1 (en) | 1998-07-30 |
EP0994717A4 (en) | 2000-07-26 |
EP0994717A1 (en) | 2000-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5935577A (en) | Treatment of autoimmune disease using tolerization in combination with methotrexate | |
AU720695B2 (en) | Bystander suppression of autoimmune diseases | |
US6645504B1 (en) | Bystander suppression of type I diabetes by oral administration of glucagon | |
AU6648898A (en) | Treatment of autoimmune disease using tolerization in combination with methotrexate | |
WO1998032451A9 (en) | Treatment of autoimmune disease using tolerization in combination with methotrexate | |
Miller et al. | Epitopes of myelin basic protein that trigger TGF-beta release after oral tolerization are distinct from encephalitogenic epitopes and mediate epitope-driven bystander suppression. | |
EP1033998B1 (en) | Suppressing beta-amyloid-related changes in alzheimer's disease | |
AU9023791A (en) | Treatment of autoimmune diseases by oral administration of autoantigens | |
EP0506785A1 (en) | Improved treatment of autoimmune diseases by aerosol administration of auto antigens | |
AU695883B2 (en) | Treatment of autoimmune disease using oral tolerization and/or Th2-enhancing cytokines | |
AU686797B2 (en) | Treatment of autoimmune disease using oral tolerization and/or type I interferon | |
US20010007758A1 (en) | Treatment of multiple sclerosis using COP-1 and Th2-enhancing cytokines | |
US20040115217A1 (en) | Bystander suppression of autoimmune diseases | |
WO1994004121A1 (en) | Bystander suppression of retroviral-associated neurological disease | |
EP2081584A2 (en) | Treatment of inflammation, demyelination and neuronal/axonal loss | |
JP2001502306A (ja) | インシュリン依存性糖尿病の処置方法および組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |